Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome

Emma H. Kaplan, Elizabeth A. Offermann, Jacqueline W. Sievers, Anne M. Comi

Research output: Research - peer-reviewArticle

Abstract

Background Sturge-Weber syndrome results in leptomeningeal vascular malformations, medically refractory epilepsy, stroke(s), and cognitive impairments. Cannabidiol, a cannabinoid without psychoactive properties, has been demonstrated in preclinical models to possibly have anticonvulsant, antioxidant, and neuroprotective actions. Methods Five subjects with Sturge-Weber syndrome brain involvement and treatment-resistant epilepsy were enrolled. Motor seizure frequency, quality of life, and adverse events were recorded from the eighth week of the pretreatment period, eight weeks after starting maintenance dose (week 14), and the most recent visit. Results Four subjects had data through week 14, one of whom initially withdrew for lack of efficacy but because of other benefits re-enrolled with a lower dose. Two subjects at week 14 and three subjects with bilateral brain involvement had at the last visit a greater than 50% seizure reduction, reported an improved quality of life, and remained on cannabidiol 63-80 weeks after starting the drug. Three subjects reported mild side effects considered related to cannabidiol. Conclusion This study suggests that cannabidiol may be well tolerated as adjunctive medication for seizure management and provides initial data supporting further study of cannabidiol in individuals with Sturge-Weber syndrome.

LanguageEnglish (US)
Pages18-23.e2
JournalPediatric Neurology
Volume71
DOIs
StatePublished - Jun 1 2017

Fingerprint

Cannabidiol
Sturge-Weber Syndrome
Seizures
Epilepsy
Quality of Life
Brain
Vascular Malformations
Cannabinoids
Anticonvulsants
Antioxidants
Stroke
Pharmaceutical Preparations
Cognitive Dysfunction

Keywords

  • cannabidiol
  • intractable epilepsy
  • safety
  • Sturge-Weber syndrome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. / Kaplan, Emma H.; Offermann, Elizabeth A.; Sievers, Jacqueline W.; Comi, Anne M.

In: Pediatric Neurology, Vol. 71, 01.06.2017, p. 18-23.e2.

Research output: Research - peer-reviewArticle

Kaplan, Emma H. ; Offermann, Elizabeth A. ; Sievers, Jacqueline W. ; Comi, Anne M./ Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. In: Pediatric Neurology. 2017 ; Vol. 71. pp. 18-23.e2
@article{643ee4b4f5b44b8ab8554cf7dbe8e7ff,
title = "Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome",
abstract = "Background Sturge-Weber syndrome results in leptomeningeal vascular malformations, medically refractory epilepsy, stroke(s), and cognitive impairments. Cannabidiol, a cannabinoid without psychoactive properties, has been demonstrated in preclinical models to possibly have anticonvulsant, antioxidant, and neuroprotective actions. Methods Five subjects with Sturge-Weber syndrome brain involvement and treatment-resistant epilepsy were enrolled. Motor seizure frequency, quality of life, and adverse events were recorded from the eighth week of the pretreatment period, eight weeks after starting maintenance dose (week 14), and the most recent visit. Results Four subjects had data through week 14, one of whom initially withdrew for lack of efficacy but because of other benefits re-enrolled with a lower dose. Two subjects at week 14 and three subjects with bilateral brain involvement had at the last visit a greater than 50% seizure reduction, reported an improved quality of life, and remained on cannabidiol 63-80 weeks after starting the drug. Three subjects reported mild side effects considered related to cannabidiol. Conclusion This study suggests that cannabidiol may be well tolerated as adjunctive medication for seizure management and provides initial data supporting further study of cannabidiol in individuals with Sturge-Weber syndrome.",
keywords = "cannabidiol, intractable epilepsy, safety, Sturge-Weber syndrome",
author = "Kaplan, {Emma H.} and Offermann, {Elizabeth A.} and Sievers, {Jacqueline W.} and Comi, {Anne M.}",
year = "2017",
month = "6",
doi = "10.1016/j.pediatrneurol.2017.02.009",
volume = "71",
pages = "18--23.e2",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome

AU - Kaplan,Emma H.

AU - Offermann,Elizabeth A.

AU - Sievers,Jacqueline W.

AU - Comi,Anne M.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background Sturge-Weber syndrome results in leptomeningeal vascular malformations, medically refractory epilepsy, stroke(s), and cognitive impairments. Cannabidiol, a cannabinoid without psychoactive properties, has been demonstrated in preclinical models to possibly have anticonvulsant, antioxidant, and neuroprotective actions. Methods Five subjects with Sturge-Weber syndrome brain involvement and treatment-resistant epilepsy were enrolled. Motor seizure frequency, quality of life, and adverse events were recorded from the eighth week of the pretreatment period, eight weeks after starting maintenance dose (week 14), and the most recent visit. Results Four subjects had data through week 14, one of whom initially withdrew for lack of efficacy but because of other benefits re-enrolled with a lower dose. Two subjects at week 14 and three subjects with bilateral brain involvement had at the last visit a greater than 50% seizure reduction, reported an improved quality of life, and remained on cannabidiol 63-80 weeks after starting the drug. Three subjects reported mild side effects considered related to cannabidiol. Conclusion This study suggests that cannabidiol may be well tolerated as adjunctive medication for seizure management and provides initial data supporting further study of cannabidiol in individuals with Sturge-Weber syndrome.

AB - Background Sturge-Weber syndrome results in leptomeningeal vascular malformations, medically refractory epilepsy, stroke(s), and cognitive impairments. Cannabidiol, a cannabinoid without psychoactive properties, has been demonstrated in preclinical models to possibly have anticonvulsant, antioxidant, and neuroprotective actions. Methods Five subjects with Sturge-Weber syndrome brain involvement and treatment-resistant epilepsy were enrolled. Motor seizure frequency, quality of life, and adverse events were recorded from the eighth week of the pretreatment period, eight weeks after starting maintenance dose (week 14), and the most recent visit. Results Four subjects had data through week 14, one of whom initially withdrew for lack of efficacy but because of other benefits re-enrolled with a lower dose. Two subjects at week 14 and three subjects with bilateral brain involvement had at the last visit a greater than 50% seizure reduction, reported an improved quality of life, and remained on cannabidiol 63-80 weeks after starting the drug. Three subjects reported mild side effects considered related to cannabidiol. Conclusion This study suggests that cannabidiol may be well tolerated as adjunctive medication for seizure management and provides initial data supporting further study of cannabidiol in individuals with Sturge-Weber syndrome.

KW - cannabidiol

KW - intractable epilepsy

KW - safety

KW - Sturge-Weber syndrome

UR - http://www.scopus.com/inward/record.url?scp=85018672819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018672819&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2017.02.009

DO - 10.1016/j.pediatrneurol.2017.02.009

M3 - Article

VL - 71

SP - 18-23.e2

JO - Pediatric Neurology

T2 - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

ER -